Growth Hormone AxisPlausible but unproven in humans

GHRH(1-29)

Sermorelin, GHRH(1-29) fragment

The GHRH(1-29) fragment, the shortest fully active GHRH sequence, used to stimulate physiologic, pulsatile growth hormone secretion.

GH / IGF-1 Recovery Sleep

GHRH(1-29)

Sequence

~12 min

Half life

503A compounded

US availability

Mechanism of action

How Sermorelin works

The shortest fully active piece of GHRH, it tells the pituitary to release growth hormone in natural, physiologic pulses.

Sermorelin

GHRH(1-29)

GHRH receptor

Pituitary

Pulsatile GH

Physiologic

↑ IGF-1

GH axis

Also studied

Stimulates pituitary GH in physiologic pulses with a short (~12 min) half life; originally a pediatric GH deficiency therapy and diagnostic.

See related compounds

Typically dosed at night to align with the body's natural nocturnal growth hormone release.

See related compounds

Applications

Research applications

GH stimulation

Pediatric GHD / diagnostic

Controlled human trial

Former approved use (Geref)

Adult GH optimization

Anti aging (off label)

Human pilot data

Efficacy unproven

Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.

Compound data

Molecular profile

CAS number86168-78-7

Molecular formulaC149H246N44O42S

Molecular weightabout 3357.9 g/mol

TypeGHRH(1-29) amide

SequenceHuman GHRH(1-29)-NH₂ (GRF 1-29)

AppearanceWhite lyophilized powder

Full profile

Evidence, safety & status

Claimed benefits & evidence

Originally a pediatric GH deficiency therapy and diagnostic, now prescribed off label for adult 'anti aging'/GH optimization. Human efficacy for anti aging endpoints is not established.

Safety & dangers

Injection site reactions, flushing, headache; IGF-1 mediated theoretical risks.

Regulatory status

Was FDA approved as Geref (discontinued 2008 for commercial reasons; approval withdrawn 2009, NOT for safety/efficacy, which legally enables compounding). Available only via 503A/503B compounding by prescription. WADA prohibited (S2, named GHRH analog).

Administration

Subcutaneous, typically at night.

Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. Anyone considering these compounds should consult a qualified physician.

For research use only

For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.